CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Drug bioavailability

How to more accurately predict human drug bioavailability?


Accurately predicting the bioavailability of drugs in humans during preclinical development is necessary to set safe and effective doses in the clinic.

Extrapolating PK parameters from animals to humans during drug development is challenging. The overall correlation between animal and human bioavailability is poor mainly due to differences in physiology and metabolic capacity.

Insufficient bioavailability in humans requires an increase in drug dose to be effective, but this comes with an increased risk of toxicity and side effects.

Our solution

We have developed the PhysioMimix™ multi-organ Gut/Liver-on-a-chip, which recapitulates the structure and function of the human tissues and their fluidic interaction, for comparing intravenous and oral compound dosing. Used in the PhysioMimix™ Bioavailability Assay, this model uniquely recreates the combined effect of intestinal permeability and first-pass metabolism by the liver for the prediction of human oral bioavailability.

Our assay provides robust preclinical data to help to overcome poor animal model bioavailability predictions and validate in silico PBPK modeling for more informed decision-making ahead of clinical trials.

Take a tour of our bioavailability animation

Drug bioavailability cells

Studying drug bioavailability

Limitations with current techniques

  • Animal models fail to accurately predict human bioavailability
  • Animal models have varying expression levels for enzymes that drive drug metabolism in humans
  • Simple in vitro models cannot model the systemic effects of the drug
  • In silico models are dependent on quality input parameters that rely heavily on early in vitro and animal studies

Advancements with PhysioMimix OOC

  • Enables the direct, accurate measurement of bioavailability using a human-relevant system
  • Perfusion of microtissues promotes the metabolic capacity of cells
  • Allows the combined effects of intestinal permeability and human liver metabolism to be explored
  • Data derived using a human-relevant approach better informs in-silico models

​

​

Modeling an orally administered drug’s route of entry


Uniquely recreate the combined effect of intestinal permeability and first-pass metabolism in vitro using a multi-organ Gut/Liver-on-a-chip for predicting human oral bioavailability. 

Modeling an orally administered drug’s route of entry graphic

​

​

Improve bioavailability predictions with an in vitro alternative to animals


Oral and IV dosing regimens can be simulated on the multi-organ gut/liver model to provide a better prediction than animal studies of human bioavailability.

Improved bioavailability graph
MPS v Animal comparison graph

Access our ADME Service


Get instant access to PhysioMimix Bioavailability Assay via our CRO Service. Through a collaborative approach, our experts work with you to plan and execute your study.

Standard and bespoke projects are carried out by our dedicated team of scientists in our CRO facility providing you with actionable data within weeks.

Learn more

Add PhysioMimix OOC into your lab


Harness the power of PhysioMimix OOC in your own lab with the purchase of a single- or multi-organ microphysiological system.

With a growing community of users and support from our experts, there has never been a better time to transition into 3D cell culture.

Learn more

Featured resources

Application notes

Improved Prediction MPS graphic |

Improved prediction of oral bioavailability using a gut-liver microphysiological system

Scientific publications

Roche 2022 |

Application of a gut–liver-on-a-chip device and mechanistic modeling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil

Articles

Toolkit |

Predicting Drug Bioavailability with the Modern-Day Toolkit

View all Drug bioavailability related resources

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023